RBC Capital raised the firm’s price target on Xencor to $34 from $31 and keeps an Outperform rating on the shares after meeting with its management team. The discussion focused on the rationale and the designs of the newly added programs – TL1A, CD19/CD20 TCEs – which should play to Xencor’s protein engineering and TCE strengths, the analyst tells investors in a research note. Given the “sharpened focus” and more shots of goal for valuation expansion, the firm is incorporating the new immunology programs into its model, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Morning Movers: Designer Brands sinks following quarterly results
- Xencor 6.64M share Spot Secondary priced at $18.00
- Xencor announces offering of common stock and warrants, no amount given
- Xencor jumps after announcing four new XmAb programs
- Xencor Reports Progress in Oncology and Autoimmune Therapies
Questions or Comments about the article? Write to editor@tipranks.com